Detalhe da pesquisa
1.
Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative neoadjuvant trial in high-risk localized prostate cancer.
Prostate
; 81(7): 418-426, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33755225